Latest Stock Market News

Gold loans by commercial banks surged by 68% in the first nine months of FY25 due to rising gold prices. Non-bank lenders also saw a rise in gold loan sanctions. The increase in gold prices has allowed lenders to offer higher loan amounts due to higher collateral value, enhancing lender comfort despite regulatory scrutiny on gold loan portfolios.

The Reserve Bank of India s recent notification aimed at promoting the use of the Indian rupee for international transactions has raised questions about the ability of Russian banks to invest in Indian stocks using funds from special Vostro accounts. Legal experts believe such transactions may be possible, but custodians await RBI s clarification.

The drop was sharper in the broader market with the Nifty Midcap 150 declining 1% and the Nifty Smallcap 250 falling 1.7%. Out of the 4,184 stocks traded on the BSE, 1,075 advanced and 2,962 declined on Monday.

In its December 2024 quarterly results, NSE Clearing, the exchange s unit responsible for clearing and settlement of its trades, reported a shortfall of ₹176.65 crore in its minimum liquid assets. The company informed Sebi in a letter dated January 9, that this deficit was primarily due to the non-receipt of ₹312.37 crore in dues from BSE.

Yields inched up at open and peaked at 6.7100% after a bigger-than-expected government borrowing target for next fiscal year.

Sebi had earlier returned Gaekwad s application, citing non-compliance with its regulations. Gaekwad said he is ready to establish an escrow arrangement upon Sebi s approval and sought necessary approval from the Reserve Bank of India. He has also appointed PL Capital Markets as the merchant banker for this bid.

Danny Gaekwad Developments & Investments has requested Sebi to allow a public announcement for competing offer against Burmans open offer for Religare Enterprises Ltd. They are also seeking to deposit Rs 60 crore in an escrow account and a bank guarantee of Rs 540 crore from RBI.

Drug maker Alembic Pharma on Monday reported Rs 138 crore net profit in Q3FY25, which is 23% year-on-year (YoY) decline compared to corresponding period of previous year, led by lacklustre growth in India business due to headwinds in the acute segment, despite strong sales growth in US and rest-of-the-world businesses.

Gland Pharma on Monday reported 7% year-on-year (YoY) rise in net profit to Rs 205 crores in Q3FY25.

HFCL reported an 11.95% fall in consolidated profit after tax to Rs 72.58 crore for Q3FY25. The consolidated revenue declined by 1.97% year-on-year to Rs 1,011.95 crore. On a standalone basis, HFCL posted quarterly revenue of Rs 960.94 crore, with a PAT of Rs 78.48 crore.